Coherus Biosciences | CHRS - Operating Profit


Coherus Biosciences reported $-39.08M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 6.88B 156M Sep/2026
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
ALKERMES USD -65.93M 17.65M Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amarin USD -2.26M 564K Dec/2025
Amgen USD 4.61B 777M Jun/2026
Baxter International USD 314M 38M Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Eli Lilly USD 12.46B 2.68B Jun/2026
Fujifilm JPY 101.76B 11.79B Mar/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Merck USD 7.33B 6.49B Sep/2026
Myriad Genetics USD -3M 20.3M Dec/2025
Pacira USD 9.96M 5.33M Jun/2026
Perrigo USD 23.5M 10.1M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
PTC Therapeutics USD 148.98M 103.09M Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Teva Pharmaceutical Industries USD 235M 523M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026
Xencor USD -36.6M 41.26M Jun/2026
Zoetis USD 1.12B 256M Jun/2026